Brookfield Asset Management and Caisse de dépôt et placement du Québec (CDPQ) are in advanced discussions to acquire Antylia Scientific from GTCR in a transaction that could value the life sciences diagnostics firm at approximately $1.4bn, according to Bloomberg.

The deal underscores sustained private equity interest in healthcare, where recurring revenue models and demand for next-generation diagnostics continue to attract institutional capital. Antylia, formerly Cole-Parmer, supplies critical products to the biopharma, environmental, and life sciences industries.

GTCR, which currently owns Antylia, declined to comment, as did representatives from Brookfield and CDPQ.

If completed, the acquisition would extend Brookfield’s active investment streak in 2025, following its $4.5bn dividend recapitalisation of Clarios International and a $1.7bn all-cash acquisition of nVent Electric’s heating cables division.

For CDPQ, the transaction reflects its strategy of increasing direct private equity exposure while forming partnerships with other major investors. The Canadian pension manager oversees approximately $330bn in assets and continues to emphasise long-term investment in scalable, defensible platforms.

The potential Antylia deal also comes amid broader sector activity, with CVC Capital Partners said to be weighing options for its stake in French diagnostics company Sebia, which could be valued at $6.5bn.